One of the most devastating developments that can occur in breast cancer is if the cancer metastasises to the brain. When this occurs prognosis is very poor due to the paucity of treatment options- limited to surgery and radiation- and fewer than two percent of these patients survive beyond two years. However, a new study dissecting the genetic markers that characterise breast cancer that spreads to the brain may offer new hope for future development of targeted small molecule drugs. The study, published in the scientific journal PLOS ONE, was led by scientists in the Translational Genomics Research Institute (TGen) in Phoenix, Arizona. Its purpose was to elucidate both common and rare events underlying metastases of breast cancer to the brain.